RALA and cancer: In various cancers, KRAS is abnormally activated when stimulated by certain signaling factors, thus activating downstream signaling pathways, including the mitogen-activated protein kinase pathway, the phosphoinositide 3-kinase signaling pathway, the Ral guanine nucleotide dissociation stimulator-Ral signaling pathway, and other signaling pathways that promote cell survival and proliferation[5].